Holen Sie sich die Stockscreener-App
53.45
1.94%
-0.69
Schlusskurs vom Vortag:
$54.14
Offen:
$54.62
24-Stunden-Volumen:
11,328
Relative Volume:
0.03
Marktkapitalisierung:
$2.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-11.77
EPS:
-4.54
Netto-Cashflow:
$-146.15M
1W Leistung:
-12.03%
1M Leistung:
-11.96%
6M Leistung:
+5.27%
1J Leistung:
+72.15%
1-Tages-Spanne:
$53.09
$54.62
1-Wochen-Bereich:
$52.63
$60.58
52-Wochen-Spanne:
$27.31
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| KROS | 53.28 | 2.19B | 0 | -168.05M | -146.15M | -4.54 |
| VRTX | 445.81 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 735.95 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 584.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.25 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Long Term Trading Analysis for (KROS) - Stock Traders Daily
What is Leerink Partnrs’ Estimate for KROS FY2024 Earnings? - Defense World
Equities Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
What is HC Wainwright's Estimate for KROS FY2024 Earnings? - MarketBeat
Wedbush Decreases Earnings Estimates for Keros Therapeutics - MarketBeat
William Blair Issues Pessimistic Forecast for KROS Earnings - MarketBeat
Leerink Partnrs Has Negative Outlook of KROS FY2024 Earnings - MarketBeat
Wedbush Equities Analysts Cut Earnings Estimates for KROS - Defense World
FY2024 Earnings Estimate for KROS Issued By HC Wainwright - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - Defense World
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023) - Yahoo Finance
Brokers Offer Predictions for KROS Q3 Earnings - Defense World
Q3 Earnings Estimate for KROS Issued By Wedbush - MarketBeat
Interesting KROS Put And Call Options For April 2025 - Nasdaq
HC Wainwright Reaffirms Buy Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Brokers Set Expectations for KROS Q4 Earnings - Defense World
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
KROSKeros Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Keros Therapeutics to Present at Guggenheim Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times
Brokers Issue Forecasts for KROS Q4 Earnings - MarketBeat
Wedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy - MarketBeat
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire
Jefferies starts Keros Therapeutics with buy, $107 target By Investing.com - Investing.com Canada
(KROS) Proactive Strategies - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
(KROS) Trading Signals - Stock Traders Daily
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK
Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat
Objective long/short (KROS) Report - Stock Traders Daily
Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Marshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Dimensional Fund Advisors LP Sells 3,691 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLC - Defense World
Squarepoint Ops LLC Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):